Peripheral arterial ischemic events in cancer patients

Vascular Medicine

Volumn 16, Issue 2, 2011, Pages 119-130

  Sanon, Saurabh ^a   Lenihan, Daniel J ^b   Mouhayar, Elie ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

arterial ischemic event; arterial occlusive diseases; arterial thromboembolic events; arterial thrombosis; cancer; thromboembolism; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ASPARAGINASE; BEVACIZUMAB; CISPLATIN; ERYTHROPOIETIN; FLUOROURACIL; GEMCITABINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN; SORAFENIB; SUNITINIB; THALIDOMIDE;

ACUTE HEART INFARCTION; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AMYLOIDOSIS; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; AORTA ANEURYSM; AORTA ATHEROSCLEROSIS; AORTA THROMBOSIS; ARTERY THROMBOSIS; ARTICLE; ARTIFICIAL EMBOLISM; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BLOOD COMPONENT THERAPY; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CAROTID ARTERY ANEURYSM; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY THROMBOSIS; CRITICAL LIMB ISCHEMIA; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIGITAL ISCHEMIA; DYSLIPIDEMIA; ENDOCARDITIS; EPIDEMIOLOGICAL DATA; ERYTHROCYTE TRANSFUSION; ERYTHROCYTOSIS; GASTROINTESTINAL STROMAL TUMOR; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TUMOR; HEART VALVE PROSTHESIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; KIDNEY CANCER; LEUKAPHERESIS; LIMB ISCHEMIA; LIVER CANCER; LOW DRUG DOSE; METABOLIC SYNDROME X; MITRAL VALVE STENOSIS; MORBIDITY; MORTALITY; MYELOPROLIFERATIVE DISORDER; NEUROFIBROMATOSIS; NON BACTERIAL THROMBOTIC ENDOCARDITIS; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYCYTHEMIA VERA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RISK FACTOR; SCREENING TEST; SHOCK; SOLID TUMOR; SURGICAL THROMBECTOMY; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID CANCER; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VASOSPASM; VENOUS THROMBOEMBOLISM;

ALGORITHMS; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; ANTIPHOSPHOLIPID SYNDROME; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; ISCHEMIA; MALE; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; NEUROFIBROMATOSIS 1; PERIPHERAL ARTERIAL DISEASE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RADIATION INJURIES; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 79955451694     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X10388346     Document Type: Article

References (100)

1. Rickles FR, Edwards RL Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983 ; 62: 14-31. (Pubitemid 13070586)
2. Khorana AA, Francis CW, Culakova E., Fisher RI, Kuderer NM, Lyman GH Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006 ; 24: 484-490. (Pubitemid 46630468)
3. Khorana AA, Francis CW, Blumberg N., Culakova E., Refaai MA, Lyman GH Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008 ; 168: 2377-2381.
4. Javid M., Magee TR, Galland RB Arterial thrombosis associated with malignant disease. Eur J Vasc Endovasc Surg 2008 ; 35: 84-87. (Pubitemid 350235237)
5. El Sakka K., Gambhir RPS, Halawa M., Chong P., Rashid H. Association of malignant disease with critical leg ischaemia. Br J Surg 2005 ; 92: 1498-1501. (Pubitemid 41785288)
6. Schattner A., Klepfish A., Huszar M., Shani A. Two patients with arterial thromboembolism among 311 patients with adenocarcinoma of the pancreas. Am J Med Sci 2002 ; 324: 335-338. (Pubitemid 36109327)
7. Thomas RH Hypercoagulability syndromes. Arch Intern Med 2001 ; 161: 2433-2439. (Pubitemid 33043116)
8. Kakkar AK, DeRuvo N., Chinswangwatanakul V., Tebbutt S., Williamson RC Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet 1995 ; 346: 1004-1005.
9. Falanga A., Rickles FR Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999 ; 25: 173-182. (Pubitemid 29227146)
10. Bevilacqua MP, Pober JS, Majeau GR, Fiers W., Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A 1986 ; 83: 4533-4537. (Pubitemid 16057083)
11. Contrino J., Hair G., Kreutzer DL, Rickles FR In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996 ; 2: 209-215. (Pubitemid 26054985)
12. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987 ; 88: 596-602. (Pubitemid 18014618)
13. Rickles FR, Levine M., Edwards RL Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992 ; 11: 237-248.
14. Sun NC, McAfee WM, Hum GJ, Weiner JM Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979 ; 71: 10-16. (Pubitemid 9109825)
15. Carroll VA, Binder BR The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999 ; 25: 183-197. (Pubitemid 29227147)
16. Kwaan Hcmd, Parmar S., Wang J. Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost 2003 ; 29: 283-290. (Pubitemid 36776190)
17. Lee AY, Levine MN The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999 ; 25: 137-145. (Pubitemid 29227142)
18. Rickles FR, Levine M., Edwards RL Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992 ; 11: 237-248.
19. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007 ; 110: 1723-1729. (Pubitemid 47443881)
20. Wilson WA, Gharavi AE, Piette JC International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus 2001 ; 10: 457-460. (Pubitemid 32675043)
21. Zuckerman E., Toubi E., Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995 ; 72: 447-451.
22. Tincani A., Taraborelli M., Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010 ; 9: 200-202.
23. Ideguchi H., Ohno S., Ueda A., Ishigatsubo Y. Catastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature). Lupus 2007 ; 16: 59-64. (Pubitemid 46174317)
24. Lopez JA, Ross RS, Fishbein MC, Siegel RJ Nonbacterial thrombotic endocarditis: a review. Am Heart J 1987 ; 113: 773-784. (Pubitemid 17036729)
25. Hagmann N., Perrenoud JJ, Gold G., Herrmann F., MacGee W., Michel JP Non-bacterial thrombotic endocarditis and cancer. Age Ageing 2001 ; 30: 92-93.
26. Dutta T., Karas MG, Segal AZ, Kizer JR Yield of transesophageal echocardiography for nonbacterial thrombotic endocarditis and other cardiac sources of embolism in cancer patients with cerebral ischemia. Am J Cardiol 2006 ; 97: 894-898.
27. Salem DN, Stein PD, Al-Ahmad A., et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004 ; 126 (3 suppl). 457S - 482S. (Pubitemid 39297961)
28. Iguchi Y., Kimura K., Kobayashi K., Ueno Y., Inoue T. Ischaemic stroke with malignancy may often be caused by paradoxical embolism. J Neurol Neurosurg Psychiatry 2006 ; 77: 1336-1339. (Pubitemid 44851991)
29. Di Tullio MR, Homma S. Patent foramen ovale and stroke: what should be done ? Curr Opin Hematol 2009 ; 16: 391-396.
30. Jurado J., Thompson PD Prevention of coronary artery disease in cancer patients. Pediatr Blood Cancer 2005 ; 44: 620-624. (Pubitemid 40629211)
31. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 ; 345: 1368-1377.
32. De Stefano V., Sora F., Rossi E., et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005 ; 3: 1985-1992. (Pubitemid 43086055)
33. Fass R., Haddad M., Zaizov R., et al. Recurrent peripheral arterial occlusion by leukemic cells sedimentation in acute promyelocytic leukemia. J Pediatr Surg 1992 ; 27: 665-667.
34. Posacioglu H., Apaydin AZ, Buyukkececi F., Soydan S., Durmaz I. Recurrent peripheral arterial occlusion in acute promyelocytic leukemia. EJVES Extra 2003 ; 6: 100-102. (Pubitemid 41138781)
35. Bombeli T., Karsan A., Tait JF, Harlan JM Apoptotic vascular endothelial cells become procoagulant. Blood 1997 ; 89: 2429-2442. (Pubitemid 27143290)
36. Romer LH, McLean NV, Yan HC, Daise M., Sun J., DeLisser HM IFN-gamma and TNF-alpha induce redistribution of PECAM-1 (CD31) on human endothelial cells. J Immunol 1995 ; 154: 6582-6592.
37. Landolfi R., Di Gennaro L., Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008 ; 22: 2020-2028.
38. Marchioli R., Finazzi G., Landolfi R., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005 ; 23: 2224-2232. (Pubitemid 46218714)
39. Rossi C., Randi ML, Zerbinati P., Rinaldi V., Girolami A. Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med 1998 ; 244: 49-53. (Pubitemid 28322605)
40. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995 ; 123: 656-664.
41. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978 ; ii: 1219-1222. (Pubitemid 9071903)
42. Michiels JJ, Berneman Z., Van Bockstaele D., van der Planken M., De Raeve H., Schroyens W. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006 ; 32: 174-207.
43. Wautier MP, El Nemer W., Gane P., et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/ BCAM. Blood 2007 ; 110: 894-901. (Pubitemid 47267426)
44. Falanga A., Marchetti M., Evangelista V., et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000 ; 96: 4261-4266.
45. Landolfi R., Marchioli R., Kutti J., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004 ; 350: 114-124. (Pubitemid 38056222)
46. Harrison CN, Campbell PJ, Buck G., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005 ; 353: 33-45. (Pubitemid 41007805)
47. Spivak JL Polycythemia vera: myths, mechanisms, and management. Blood 2002 ; 100: 4272-4279.
48. Streiff MB, Smith B., Spivak JL The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: a survey of American Society of Hematology members' practice patterns. Blood 2002 ; 99: 1144-1149. (Pubitemid 34547065)
49. Feng DL, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007 ; 116: 2420-2426. (Pubitemid 350145076)
50. Roberts WC, Waller BF Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 1983 ; 52: 137-146. (Pubitemid 13061341)
51. Browne RS, Schneiderman H., Kayani N., Radford MJ, Hager WD Amyloid heart disease manifested by systemic arterial thromboemboli. Chest 1992 ; 102: 304-307.
52. Berghoff M., Kathpal M., Khan F., Skinner M., Falk R., Freeman R. Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol 2003 ; 53: 725-730. (Pubitemid 36622509)
53. Liao R., Jain M., Teller P., et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001 ; 104: 1594-1597. (Pubitemid 32947519)
54. Plehn JF, Southworth J., Cornwell GG 3rd. Brief report: atrial systolic failure in primary amyloidosis. N Engl J Med 1992 ; 327: 1570-1573.
55. Murphy L., Falk RH Left atrial kinetic energy in AL amyloidosis: can it detect early dysfunction? Am J Cardiol 2000 ; 86: 244-246. (Pubitemid 30410743)
56. Yood RA, Skinner M., Rubinow A., Talarico L., Cohen AS Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983 ; 249: 1322-1324. (Pubitemid 13147782)
57. Choufani EB, Sanchorawala V., Ernst T., et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001 ; 97: 1885-1887. (Pubitemid 32217260)
58. Oderich GS, Sullivan TM, Bower TC, et al. Vascular abnormalities in patients with neurofibromatosis syndrome type I: clinical spectrum, management, and results. J Vasc Surg 2007 ; 46: 475-484.
59. Feldkamp MM, Gutmann DH, Guha A. Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci 1998 ; 25: 181-191. (Pubitemid 28368792)
60. Riccardi VM The vasculopathy of NF1 and histogenesis control genes. Clin Genet 2000 ; 58: 345-347.
61. Reubi F. Les vaisseaux et les glandes endocrines dans la neurofibromatose. Schweiz Z Pathol Bakteriol 1944 ; 7: 168-239.
62. Hamilton SJ, Friedman JM Insights into the pathogenesis of neurofibromatosis 1 vasculopathy. Clin Genet 2000 ; 58: 341-344.
63. Friedman JM, Arbiser J., Epstein JA, et al. Cardiovascular disease in neurofibromatosis 1: Report of the NF1 Cardiovascular Task Force. Genet Med 2002 ; 4: 105-111. (Pubitemid 44698568)
64. Walsh J., Wheeler HR, Geczy CL Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992 ; 81: 480-488.
65. Mannucci PM, Bettega D., Chantarangkul V., Tripodi A., Sacchini V., Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med 1996 ; 156: 1806-1810. (Pubitemid 26295225)
66. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 1988 ; 6: 276-281.
67. Greeno EW, Bach RR, Moldow CF Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996 ; 75: 281-289. (Pubitemid 26272366)
68. Wang J., Weiss I., Svoboda K., Kwaan HC Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001 ; 115: 382-391. (Pubitemid 34203507)
69. Bertomeu MC, Gallo S., Lauri D., Levine MN, Orr FW, Buchanan MR Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis 1990 ; 8: 511-518. (Pubitemid 20355466)
70. Feffer SE, Carmosino LS, Fox RL Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer 1989 ; 63: 1303-1307. (Pubitemid 19084550)
71. Alter P., Herzum M., Soufi M., Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006 ; 4: 1-5. (Pubitemid 43796695)
72. Dasanu CA Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008 ; 7: 703-716.
73. Cool RM, Herrington JD, Wong L. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide. Pharmacotherapy 2002 ; 22: 1200-1204. (Pubitemid 34969078)
74. Togna GI, Togna AR, Franconi M., Caprino L. Cisplatin triggers platelet activation. Thromb Res 2000 ; 99: 503-509.
75. Numico G., Garrone O., Dongiovanni V., et al. Prospective evaluation of major vascular events in patients with non-small cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005 ; 103: 994-999. (Pubitemid 40270076)
76. Grenader T., Shavit L., Ospovat I., Gutfeld O., Peretz T. Aortic occlusion in patients treated with cisplatin-based chemotherapy. Mt Sinai J Med 2006 ; 73: 810-812. (Pubitemid 44445786)
77. Pereg D., Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J 2008 ; 29: 2325-2326.
78. Grivas AA, Trafalis DT, Athanassiou AE Implication of bevacizumab in fatal arterial thromboembolic incidents. J BUON 2009 ; 14: 115-117.
79. Yoon S., Schmassmann-Suhijar D., Zuber M., Konietzny P., Schmassmann A. Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 2006 ; 17: 1851-1852. (Pubitemid 44884065)
80. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004 ; 25: 581-611. (Pubitemid 39099316)
81. Kilickap S., Abali H., Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003 ; 21: 3542 ; author reply 3543.
82. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007 ; 99: 1232-1239. (Pubitemid 47299901)
83. Choueiri TK, Schutz FA, Je Y., Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010 ; 13: 2280-2285.
84. Shahani S., Braga-Basaria M., Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008 ; 93: 2042-2049. (Pubitemid 351831513)
85. Jurado JA, Bashir R., Burket MW Radiation-induced peripheral artery disease. Catheter Cardiovasc Interv 2008 ; 72: 563-568.
86. Burger A., Loffler H., Bamberg M., Rodemann HP Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol 1998 ; 73: 401-408. (Pubitemid 28202113)
87. Riley PA Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994 ; 65: 27-33. (Pubitemid 24063526)
88. Gaugler MH, Vereycken-Holler V., Squiban C., Vandamme M., Vozenin-Brotons MC, Benderitter M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 2005 ; 163: 479-487. (Pubitemid 41490643)
89. Milutinovic J., Darcy M., Thompson KA Radiation-induced renovascular hypertension successfully treated with transluminal angioplasty: case report. Cardiovasc Intervent Radiol 1990 ; 13: 29-31. (Pubitemid 20147666)
90. Saddekni S., Sniderman KW, Hilton S., Sos TA Percutaneous transluminal angioplasty of nonatherosclerotic lesions. AJR Am J Roentgenol 1980 ; 135: 975-982. (Pubitemid 11236966)
91. Saka B., Bilge AK, Umman B., et al. Bilateral renal artery stenosis after abdominal radiotherapy for Hodgkin's disease. Int J Clin Pract 2003 ; 57: 247-248. (Pubitemid 36511790)
92. Gladding PA, Webster MW, Kay P. Late drug-eluting stent thrombosis and erythropoietin: cause and effect? Heart Lung Circ 2007 ; 16: 305-307. (Pubitemid 47010462)
93. Dusenbery KE, McGuire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994 ; 29: 1079-1084. (Pubitemid 24278975)
94. Lavey RS, Dempsey WH Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993 ; 27: 1147-1152. (Pubitemid 23361597)
95. Haddad TC, Greeno EW Chemotherapy-induced thrombosis. Thromb Res 2006 ; 118: 555-568. (Pubitemid 44414957)
96. Tobu M., Iqbal O., Fareed D., et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost 2004 ; 10: 225-232. (Pubitemid 38982046)
97. Blumberg N., Gettings KF, Turner C., Heal JM, Phipps RP An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006 ; 46: 1813-1821. (Pubitemid 44435735)
98. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006 ; 108: 2455-2462. (Pubitemid 44497533)
99. Reynolds JD, Ahearn GS, Angelo M., Zhang J., Cobb F., Stamler JS S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 2007 ; 104: 17058-17062. (Pubitemid 350210991)
100. Oktar GL, Ergul EG, Kiziltepe U. Occult malignancy in patients with venous thromboembolism: risk indicators and a diagnostic screening strategy. Phlebology 2007 ; 22: 75-79.